Lupin has received approval from the Food and Drug Administration for ipratropium bromide nasal solution (nasal spray), 0.06%, which is a generic of Boehringer Ingelheim's Atrovent Nasal Spray, 0.06%.

Lupin is introducing Minzoya (levonorgestrel and ethinyl estradiol tablets and ferrous bisglycinate tablets), 0.1 mg/0.02 mg and 36.5 mg, which is a generic of Avion’s Balcoltra. Generic Minzoya ...

Lupin has obtained approval from the USFDA to market a generic form of an HIV medication. The approved drug, equivalent to Symtuza tablets, positions Lupin as the exclusive first-to-file. The tablets ...

The US Food and Drug Administration (FDA) has approved the abbreviated new drug application (ANDA) of Lupin’s Sacubitril and Valsartan tablets for heart failure patients. Sacubitril and ...

According to IQVIA MAT December 2024, this drug will generate a U.S. market sales revenue of $1,374 million. Lupin is the first-to-file applicant for this generic product. Being the first-to-file ...

The company got the US Food and Drug Administration's nod for the 25 mg and the 50 mg dosages in October 2022. So far, only Lupin and Zydus Life have launched their generic versions of the drug.

Finance Minister Sitharaman announced the inclusion of six life-saving drugs in the concessional 5% duty slab to enhance ...

Mumbai: Global pharma major Lupin Limited and Avas Pharmaceuticals SRL have announced the launch of Lupin's orphan drug ...

Lupin and Avas Launch NaMuscla® in Italy Enables expanded access to the only EU-approved <a target=_blank href=http ...